Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,39
KB0,43
PKN121121,70,75
Msft1,16
IBM0,73
DCX68,3368,36-0,84
PFE0,50
21.10.2017 2:10:00
Indexy online
AD Index online
select
AD Index online
 

  • 20.10.2017
La Jolla Pharmaceut (NASDAQ Cons)
Závěr k 20.10.2017 Změna (%) Změna (USD) Objem obchodů (ks)
34,83 0,43 0,15 135 493
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.10.2017
Popis společnosti
Obecné informace
Název společnostiLa Jolla Pharmaceutical Company
TickerLJPC
Kmenové akcie:Ordinary Shares
RICLJPC.O
ISINUS5034596040
Prioritní akciePreference Shares Ser. C-1
Prioritní akcieConv. Pref. Shrs Series D-1
Prioritní akcieConv. Pref. Shrs Series C-2
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.6.2017
Počet zaměstnanců k 31.12.2016 105
Akcie v oběhu k 17.7.2017 22 123 456
Počet akcionářů k 31.12.2016 4 000
MěnaUSD
Kontaktní informace
Ulice10182 Telesis Ct Fl 6
MěstoSAN DIEGO
PSČ92121-4777
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon18 582 074 264
Fax16194526893

Business Summary: La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
Financial Summary: BRIEF: For the six months ended 30 June 2017, La Jolla Pharmaceutical Company revenues decreased from $487K to $0K. Net loss increased 56% to $50M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 48% to $33.5M (expense), General and administrative - other increase from $3M to $6.9M (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research



  • Poslední aktualizace: 22.10.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardKevin Tang50
President, Chief Executive Officer, Secretary, DirectorGeorge Tidmarsh5619.1.201219.1.2012
Chief Financial OfficerDennis Mulroy616.4.20156.4.2015
Senior Vice President,OperationsJennifer Carver62
Chief Medical OfficerLakhmir Chawla45